Lilly's strong results for psoriasis drug come on heels of data from Novartis

Eli Lilly ($LLY) has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab when compared with Pfizer's ($PFE) Enbrel in a head-to-head study. It said today results were good enough for it to make a regulatory filing in the first half of 2015 for its IL-17A therapy. It is trying to get to market with new products afer generic competition has been hard on its top products. The results come just days after Novartis ($NVS) reported more positive Phase III data for its IL-17 treatment secukinumab for the same condition. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.